All Stories

  1. Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

    Article • Clinical Drug Investigation, March 2018, Springer Science + Business Media

    Andriy Krendyukov

  2. Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained

    Article • BioDrugs, February 2018, Springer Science + Business Media

    Andriy Krendyukov

  3. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained

    Article • BioDrugs, February 2018, Springer Science + Business Media

    Andriy Krendyukov

  4. Extrapolation concept at work with biosimilar: a decade of experience in oncology

    Article • ESMO Open, February 2018, BMJ

    Andriy Krendyukov

  5. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies

    Article • The Oncologist, January 2018, Alphamed Press

    Andriy Krendyukov

  6. Comparing granulocyte colony–stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients

    Article • European Journal of Cancer, January 2018, Elsevier

    Andriy Krendyukov

  7. Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study


    Article • Clinical Nephrology, January 2018, Dustri-Verlgag Dr. Karl Feistle

    Andriy Krendyukov

  8. Development and 10-year history of a biosimilar: the example of Binocrit®

    Article • Therapeutic Advances in Medical Oncology, January 2018, SAGE Publications

    Andriy Krendyukov

  9. MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis

    Article • European Journal Of Haematology, December 2017, Wiley

    Andriy Krendyukov

  10. 10 years of clinical experience in the treatment of renal anemia with HX575

    Article • Drug Design Development and Therapy, December 2017, Dove Medical Press

    Andriy Krendyukov

  11. G-CSF and G-CSF Biosimilars: A Meta-Analysis of Randomized Clinical Trials in Breast Cancer Patients Undergoing Myelosuppressive Chemotherapy

    Article • The Breast, November 2017, Elsevier

    Andriy Krendyukov

  12. Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients


    Article • Clinical Nephrology, October 2017, Dustri-Verlgag Dr. Karl Feistle

    Andriy Krendyukov

  13. 1126PThe evolution of value with filgrastim in oncology

    Article • Annals of Oncology, September 2017, Oxford University Press (OUP)

    Andriy Krendyukov

  14. 1572PG-CSF and G-CSF biosimilars: a meta-analysis of randomized clinical trials in breast cancer patients

    Article • Annals of Oncology, September 2017, Oxford University Press (OUP)

    Andriy Krendyukov

  15. 1594PBiosimilar epoetin alfa (HX575) for the treatment of chemotherapy-induced anaemia: Development, approval and 10 years’ clinical experience

    Article • Annals of Oncology, September 2017, Oxford University Press (OUP)

    Andriy Krendyukov

  16. The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information

    Article • ESMO Open, August 2017, BMJ

    Andriy Krendyukov

  17. Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials

    Article • Future Oncology, April 2017, Taylor & Francis

    Andriy Krendyukov

  18. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)

    Article • Journal of Geriatric Oncology, March 2017, Elsevier

    Andriy Krendyukov

  19. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

    Article • Supportive Care in Cancer, January 2017, Springer Science + Business Media

    Andriy Krendyukov